Cytoreductive radical prostatectomy in patients with high-volume metastatic prostate cancer achieving deep biochemical response to contemporary systemic therapy: a multicentre, prospective cohort stud
4 hours ago
- #metastatic prostate cancer
- #oncological outcomes
- #cytoreductive surgery
- Investigates cytoreductive radical prostatectomy (CRP) in high-volume metastatic hormone-sensitive prostate cancer (mHSPC) patients achieving deep biochemical response (PSA <0.2 ng/ml) to contemporary systemic therapy.
- Multicentre, prospective cohort study (2018-2023) comparing CRP plus standard of care (SOC) vs. SOC alone, with primary endpoint of radiographic progression-free survival (rPFS).
- Results show CRP associated with significantly improved rPFS, overall survival (OS), and PSA progression-free survival (PSA-PFS) in high-volume disease patients, even after propensity score matching.
- Concludes CRP is feasible and may improve outcomes in selected mHSPC patients with deep response, but requires validation in larger randomized trials.